familymednews.com
Immunotherapy has revolutionized the treatment of cancer in the last decade, yet many tumors do not respond to these new therapies. A new genome-wide screen of 20,000 human genes in T cells have turned up several new candidates to unleash the immune system’s ability to attack a variety of tumor types, Yale researchers report Aug. 22 in the journal Cell. […]
Continue reading »
A novel imaging test shows promise for identifying kidney cancer patients most likely to benefit from immunotherapy. In a study published today in the Journal for ImmunoTherapy of Cancer, investigators with the UT Southwestern Medical Center Kidney Cancer Program developed a new test to illuminate kidney cancers that may respond to checkpoint inhibitors. The strategy involved transforming an immunotherapy drug, […]
Continue reading »
Two studies to be reported at ELCC 2019 provide new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC), where information has previously been lacking despite being the age group most commonly affected. Immunotherapy with drugs that target immune pathways to enhance the body’s ability to recognise and destroy tumour cells is […]
Continue reading »
A new combination of three drugs that harness the body’s immune system is safe and effective, destroying most cancer cells in 95 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study. Presented Dec. 3 at the annual meeting of the American Society of Hematology in San Diego, the study in 19 men and women […]
Continue reading »
Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100 percent of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach. Restoring patients’ immune response against cancer cells with checkpoint inhibitors is an established treatment […]
Continue reading »
Individuals with an inherited form of skin cancer often have a poor prognosis. The type of immunotherapy that was awarded this year’s Nobel Prize in Physiology or Medicine is, however, particularly effective in this patient group, research from Karolinska Institutet in Sweden shows. The study is published in the Journal of Medical Genetics. Congenital mutations of the CDKN2A gene are […]
Continue reading »
CAR T-cell therapy, which reprograms immune cells to fight cancer, has shown great promise in people with some blood cancers who have not responded to other treatments. But until now, the underlying biological pathways enabling anti-cancer responses have not been thoroughly examined. Understanding these pathways is important for designing future generations of CAR T-cell therapies, including reducing side effects, preventing […]
Continue reading »
Doctors are increasingly fighting cancer by stimulating patients’ immune systems. SNSF-supported researchers have now discovered a method for predicting the likelihood of treatment success. Immunotherapy changes a patient’s immune system to allow it to attack cancer cells and either destroy them or at least keep them from growing. But the therapy only works for a minority of patients. Researchers supported […]
Continue reading »
Cleveland Clinic researchers have demonstrated for the first time that lowering blood cholesterol levels could enhance the success of a specific type of T-cell immunotherapy in fighting cancer. The team, led by Qing Yi, MD, Ph.D., of Cleveland Clinic Lerner Research Institute studied T-cell transfer, which has shown great success in recent years. Dr. Yi previously showed that a specific […]
Continue reading »
University of Colorado Cancer Center researchers recently completed the largest-ever study of thyroid cancer genetics, mining the data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid cancers. In addition to identification of specific genes that may drive these cancers and thus provide attractive targets for treatment, the researchers found that in several samples of advanced […]
Continue reading »